Recently, well-publicized reports by Public Citizen and the Joint Economic Committee (JEC) of the US Congress questioned the role of the drug industry in the discovery and development of therapeutically important drugs. To gain a better understanding of the relative roles of the public and private sectors in pharmaceutic innovation, the Tufts Center for the Study of Drug Development evaluated the underlying National Institutes of Health (NIH) and academic research cited in the Public Citizen and JEC reports and performed its own assessment of the relationship between the private and public sectors in drug discovery and development of 21 "impact" drugs. We found that, ultimately, any attempt to measure the relative contribution of the public and private sectors to the research and development (R&D) of therapeutically important drugs by output alone, such as counting publications or even product approvals, is flawed. Several key factors (eg, degree of uncertainty, expected market value, potential social benefit) affect investment decisions and determine whether public or private sector funds, or both, are most appropriate. Because of the competitiveness and complexity of today's R&D environment, both sectors are increasingly challenged to show returns on their investment and the traditional boundaries separating the roles of the private and public research spheres have become increasingly blurred. What remains clear, however, is that the process still starts with good science and ends with good medicine.
INTRODUCTION
A recent widely publicized report has disparaged the contribution of the drug industry to the development of important new drugs. In July 2001, Public Citizen, a consumer watchdog group, released a report called "Rx R&D Myths: The Case Against the Drug Industry's R&D 'Scare Card'," which stated that "Industry R&D risks and costs are significantly reduced by taxpayer-funded research, which has helped launch the most medically important drugs in recent years . . ." 1 Industry critics have also used a report entitled "The Benefits of Medical Research and the Role of the NIH," which was issued in May 2000 by the Joint Economic Committee (JEC) of the US Congress, to minimize the role of industry in the discovery and development of innovative drugs. The JEC report focused on a group of 21 drugs introduced from 1965 to 1992 ". . . that were considered by experts to have had the highest-therapeutic impact on society . . ." 2 Public Citizen and the JEC cited research done by the National Institutes of Health (NIH) as well as a study done by economists Iain Cockburn and Rebecca Henderson in support of their claims.
The findings of the Public Citizen report regarding the relative contribution of the public and private sectors to drug discovery and development were based on one document in particular, an internal NIH study entitled "NIH Contributions to Pharmaceutical Development-Case Study Analysis of the Top-Selling Drugs." This document, which was made widely available by Public Citizen in July 2001, purported to demonstrate the respective roles of the public and private sectors in the development of five top-selling drugs through analyses of published literature. A fundamental defect underlying studies of this kind, however, is the subjective nature of assigning relevance. A count of published studies of specific drugs cannot be used to assign values to relative public and private contributions to their development, because the relevance of the studies to the ultimate approval of the drugs often cannot be determined.
The impact of publicly funded biomedical research on private sector drug discovery and development efforts was also investigated by Cockburn and Henderson. The focus of Cockburn and Henderson's work was the relationship between private sector firms' participation in "open science," as measured by counting coauthorship of scientific papers with public sector scientists, and the productivity of their in-house research. 3 Cockburn and Henderson used case histories of 21 drugs to illustrate their point, but they did not attempt quantitative analyses of the relative contributions of the public and private sectors to the discovery and development of these drugs. In fact, Cockburn and Henderson acknowledged in their paper that it was difficult to quantify the public sector's specific contribution to the industry's pool of knowledge capital. The authors surmised that this difficulty was a result of the long lags between fundamental discoveries and consequent marketed products and the ". . . complex and often bidirectional relationship between the public and private sectors . . ." 4 The authors emphasized that their analysis was an attempt to measure the extent and nature of the "connectedness" between the public and private sectors. Specifically, they examined the ability of industry to access the common pool of useful knowledge generated by public sector research, thereby enhancing industry's productivity. 5 Despite methodologic limitations noted by the authors, Cockburn and Henderson's work has been used to paint an unflattering picture of the contribution of industry to the R&D of many breakthrough drugs.
A clear counterpoint to the JEC and Public Citizen reports emerged from the most recent report by the NIH on this contentious and complex subject. In August 2001, the NIH released "A Plan to Ensure Taxpayers' Interests Are Protected." 6 The plan was devised in response to the Committee Report for the FY 2001 Department of Health and Human Services Appropriation, in which the NIH was instructed to prepare a plan to ensure taxpayers' interests are protected when the NIH invests in basic research. Specifically, the NIH was directed to review a list of US Food and Drug Administration (FDA)-approved therapeutic medicines that had $500 million per year sales in the United States and had received NIH funding when preparing the plan.
According to the NIH, only 4 of 47 drugs meeting the criteria were developed with patented technologies for which the government has use or ownership rights. This finding was derived from a review methodology that focused on practical considerations of the NIH's mission and on legal aspects of the Stevenson-Wydler Technology Innovation Act and the Patent and Trademark Amendments of 1980 (known as the Bayh-Dole Act) as implemented by the NIH. The pic-ture of the relative contribution of the public and private sectors to drug development when this methodology is used bears sharp contrast to the image portrayed in the JEC and Public Citizen reports.
Here, we first review the pertinent points of the recent analysis conducted to formulate the NIH plan to protect taxpayers' interests regarding NIHfunded research. We demonstrate that assessment of government patent rights as a measure of NIH "ownership" of a drug brings a new perspective to the question of whether the public is getting an appropriate return on the NIH investment in basic research. We next examine the studies by the NIH (as cited in the Public Citizen report) and Cockburn and Henderson, which used publications as a measure of public and private contributions to the discovery and development of specific best-selling "impact" drugs. These studies in particular have been used to imply that the NIH has ownership, at least in part, of the drugs. We explore the methodology used in these studies and discuss their limitations. Finally, we provide an independent assessment of the complex and interdependent relationship between the public and private sectors in drug discovery and development. HEALTH RESPONSE TO THE  COMMITTEE REPORT FOR THE FY  2001 DEPARTMENT OF HEALTH  AND HUMAN SERVICES  APPROPRIATION INSTRUCTION:  A PLAN TO ENSURE TAXPAYERS'  INTERESTS ARE PROTECTED  (RELEASED AUGUST 2001) The following instructions were given to the NIH in the Committee Report for the FY 2001 Department of Health and Human Services Appropriation: "The conferees have been made aware of the public interest in securing an appropriate return on the NIH investment in basic research. The conferees are also aware of the mounting concern over the cost to patients of therapeutic drugs. By July 2001, based on a list of such therapeutic drugs which are FDA approved, have reached $500 million per year in sales in the United States, and have received NIH funding, NIH will prepare a plan to ensure that taxpayers' interests are protected." 7 In responding to the instructions, the NIH noted the legal framework by which it is bound, described the process the NIH uses to fund research, discussed the methodology and findings, and then proposed a plan. The overall conclusion was that the "NIH and its recipient institutions apply the provisions of Bayh-Dole to best advantage in seeking the optimal return on investment in terms of public health benefit." 8 After noting the difficulty in associating particular NIH grants and contracts that gave rise to inventions with patents or licenses for the final product, the NIH proposed a plan to initiate better information collection and development of a web-based database that would allow the NIH to make the required associations.
NATIONAL INSTITUTES OF
The key phrase of the conclusion was "apply the provisions of Bayh-Dole." The NIH has strict limitations under the Bayh-Dole Act-it does not have title to grant-supported or contract-supported (extramural) research discoveries and cannot dictate terms for licensing or commercialization of the work. Support for this extramural research, which is done by non-Federal researchers at academic, medical, and research institutions in the United States and abroad, accounts for nearly 84% of the NIH budget. 9 As per the instructions, the NIH identified 47 drugs that fit the designated criteria and then determined whether the government, either directly or through a grantee or contractor, held patent rights or was designated as having an interest in the patents of the 47 drugs. The NIH found that the "NIH has Government use or ownership rights to patented technologies used in the development of four of those drugs. The NIH case study report* was undertaken to determine whether and to what extent public funding of research enabled the development of certain medically or commercially successful products. Additionally, this study began to lay a basis for discussing the specific ways by which those who expand fundamental understanding of the workings of the natural world are as important to technologic advances as those who implement that knowledge. 11 The NIH case study report was prepared from an analysis of review articles identified by Medline searches of the chemical name of the drugs and original research articles cited by the reviews. The literature selected for inclusion in the report was focused on basic research as stated in the methodology section: "The scientific discoveries that led to the necessary concepts and techniques were identified, along with the names and affiliations of the scientists performing the work. Rather than attempt to identify a small number of 'key papers,' which does not accurately represent the way scientific ideas develop in the research community, the approach taken was to identify major areas of research which led to drug discovery [emphasis added] and the individuals or laboratories who were significantly involved." Despite the focus on basic research, the report included sections listing publications in the areas of "drug development and testing" and "clinical trials."
We examined the NIH case study report and found the study to be limited in the following ways:
• The methodology is inherently biased toward public sector input. Specifically, public sector scientists have a much greater incentive to publish than do industry scientists. • Industry contribution is underestimated, because a number of publications coauthored by academic and industry scientists are assigned only to public sector affiliation. A category for the coauthored publications, the main focus of Cockburn and Henderson's work, does not exist in the NIH case study report. • The list of published studies included in the sections on drug development and testing and clinical trials is not complete. As a result, these sections cannot be used for quantitative analyses. • Industry contribution could be underestimated, because complete information on the funding of the published studies is not provided. Thus, although the scientist's affiliation might be academic, funding for the work might have been wholly, or in part, from industry. • No information is given as to whether the NIH grants were for extramural or intramural research. The distinction has implications because of the legal limitations on NIH ownership of technology resulting from extramural work. Their work has been cited by the NIH, the JEC, and by Public Citizen. As part of their work, Cockburn and Henderson constructed case histories for a group of 21 drugs that were considered to have had the most impact on therapeutic practice between 1965 and 1992. They then attempted to answer two questions concerning the drugs. These two questions were:
1. Was the key enabling discovery made by a scientist working in the public sector? (Yes/No) 2. Was the drug first synthesized or isolated by a scientist working in the public sector? (Yes/No)
Answers to the first question led Cockburn and Henderson to state that "only 5 of these drugs, or 24%, were developed with essentially no input from the public sector." 12, 13 This particular statement has been cited in various ways. The JEC cites the Cockburn and Henderson working paper and states, "71% (15 drugs) were developed with input from the public sector." 14 Public Citizen cites the same paper and states, "A study by a Massachusetts Institute of Technology (MIT) scholar of the 21 most important drugs introduced between 1965 and 1992 found that publicly funded research played a part in discovering and developing 14 of the 21 drugs (67%)." 15 The NIH case study report cites an unpublished version of the work prepared for a conference in June 1996 and declares, "among these 21 drugs, publicly funded research was instrumental to the development of 16, or 76%." 16 These statements by the JEC, Public Citizen, and the NIH are alike in one important way-none of them mention the fact that the "publicly funded research" was for key enabling discoveries only. Cockburn and Henderson provide this information for 19 of the 21 drugs in the working paper (key enabling discoveries for 14 are assigned to public sector scientists). Interestingly, the JEC, Public Citizen, and the NIH make no reference to the answers to their second question. Cockburn and Henderson's second result was that 14 of the drugs were first synthesized by industrial scientists (information provided for 18 of the 21 drugs).
USE AND MISUSE OF THE NATIONAL INSTITUTES OF HEALTH CASE STUDY REPORT AND COCKBURN AND HENDERSON'S WORK
The NIH case study report and Cockburn and Henderson's work are in agreement in their finding that publicly funded research efforts in medicine and the pharmaceutical industry's research and development efforts are, on the whole, complementary. Publicly funded research tends to focus on basic science, whereas the pharmaceutical industry tends to focus on applied research and clinical studies of promising drugs, although there is some overlap of these areas.
The NIH should be recognized for its long history of achievements and contributions to medicine, and for its five Nobel laureate scientists. In addition, the NIH has funded excellent science over the years as evidenced by the 93 Nobel Prizes won by NIH-funded scientists. 17 The pharmaceutical industry should also be recognized for its excellent research and development efforts, which have resulted in the approval for marketing of 438 new medicines in the United States during the last 20 years, 18 and for the three scientists who won Nobel Prizes while working in the private sector.
Both the NIH and the research-based pharmaceutical industry have sponsored studies designed to illustrate the importance of their work. Issues arise when "facts," some of which are incorrect or taken out of context, from these studies are used in an attempt to demonstrate the greater value of one group's efforts compared with the other. Both the NIH and the pharmaceutical industry are vulnerable to criticism. The NIH is sensitive to criticism that a proportion of its funding goes to projects that do not produce tangible results. The pharmaceutical industry is equally sensitive to criticism that all the hard work of drug discovery is done by publicly funded researchers and that industry unfairly profits by simply marketing the resulting drugs.
Counting publications that involve use of drugs is a biased way of assigning ownership of drugs. The NIH's ownership of medical research cannot be determined by counting the number of new medicines it markets, because the NIH is not in the business of marketing drugs. By the same token, the pharmaceutical industry's ownership of marketed drugs cannot be determined by counting publications, because industrial scientists typically produce commercial products rather than publications.
TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT INVESTIGATION: PUBLIC AND PRIVATE SECTOR CONTRIBUTIONS TO THE DISCOVERY AND DEVELOPMENT OF IMPACT DRUGS
We independently studied the case histories of the 21 impact drugs included in Cockburn and Henderson's work. Using an approach similar to that described in the NIH case study report, we searched the published literature for information on the discovery and development of the drugs. We noted the affiliation and location of the authors, the source of funding for the work (if provided by authors), and the date of the study (if provided) or publication. We restricted our search to papers that pertained to a given drug and were published between the year of the synthesis of the drug and 2 years after FDA approval of the drug. † We did not duplicate the study of the enabling discoveries done by both the NIH and Cockburn and Henderson but focused only on published studies that reported properties (eg, chemical, physical, toxicologic, pharmacokinetic/dynamic, therapeutic) of the actual drugs. The 21 drugs we studied are listed in Table 1 .
The following points should be noted:
• The limitations inherent in our methodology were the same as for the NIH case study report. Industry contributions tended to be underestimated be-cause contributions were assigned to published work only. • Our results, like those in the NIH case study report, cannot be used for quantitative analyses. We identified hundreds of publications that met our criteria; some of the publications were hundreds of pages in length (these were proceedings of symposia). It was not possible to ascertain whether we found all pertinent publications (eg, only publications in English were included). • There was substantial non-US involvement in the discovery and development work done for the 21 drugs. The majority of the drugs were synthesized, patented, or first launched outside the United States, which complicated any analyses of the relative contributions of the public and private sectors. • The relevance of any clinical studies funded wholly or in part by the NIH to the approval of the drug could not be determined.
Our study illustrates the complex interactions of the US public sector, especially the NIH, and the private sector in the discovery and development of drugs. For this set of 21 drugs, we noted that the involvement of the NIH, usually in the form of extramural research funding, was greatest in the preclinical and clinical development of drugs that were treatments for serious or life-threatening diseases such as acquired immunodeficiency syndrome or cancer. There was clearly a public health benefit derived from facilitating the development of these drugs. The NIH was also involved in the discovery and/or development of compounds that were in the "public domain," (ie, knowledge of the existence and method of preparation of the compounds was publicly available before therapeutic potential was identified). Three of the drugs (AZT [azidothymidine], cisplatin, and foscarnet) were synthesized well before biologic activity was observed. These types of compounds initially might not have been of interest to the pharmaceutical industry, because possible patent claims were limited.
Having acknowledged the contribution of the public sector, particularly the NIH, in the development of the impact drugs just discussed, it is important to note that the NIH cannot patent or in any other way claim ownership of drugs simply by funding studies. It is also necessary to place the part played by NIH-funded trials in the overall picture of drug development. No one would argue the fact that during the period in which many of the 21 drugs from our review were in active development, public funding in real terms in the United States for health-related research increased by 200%. 19 Most of that health-related research was † Additional clinical testing funded by the US public sector may have occurred after the drugs were approved for marketing. It is important to note that after approval, drugs may be tested in clinical studies by any qualified investigator. Because the drug is commercially available, the FDA does not necessarily have to be informed of the clinical studies (although institutional review board and informed consent regulations still apply) and involvement or consent of the manufacturer is not required. not focused on pharmaceutic agents, however. The NIH's definition of "clinical research" has been criticized as being too inclusive because it encompasses not only clinical trials but also mechanisms of human disease, therapeutic interventions, development of new technologies, epidemiologic and behavioral studies, and outcomes and health services research. 20 According to a recent study by the General Accounting Office, even the NIH's use of the term clinical trials includes a range of research activities encompassing testing of new approaches to disease prevention, diagnosis, or treatment. 21 The General Accounting Office report further acknowledges that although both the NIH and pharmaceutical companies are the major sponsors of clinical trials that focus on drugs, devices, and vaccines, the NIH-supported trials also address prevention strategies and surgical procedures and may target special populations such as patients with rare diseases. 22 The pharmaceutical industry, in contrast, typically supports the large clinical trials that determine therapeutic efficacy of new drug products for conditions that affect large numbers of people. 23 "NOBEL PRIZE-WINNING" DRUG RESEARCH: THE PRODUCT OF TIME, CAPITAL, AND MANPOWER The importance of the contribution of the private sector to drug discovery and development was acknowledged when the 1988 Nobel Prize in Physiology or Medicine was awarded to Dr George Hitchings, Ms Gertrude Elion, and Sir James Black for their discoveries of important principles for drug treatment. Hitchings and Elion, working at Burroughs Wellcome, contributed to the discovery and development of acyclovir. ‡ at Imperial Chemical Industries and later at Smith Kline & French. § The history of the discovery and development of the drugs that garnered their inventors the coveted Nobel Prize illustrates another point-drug development is a resource-intensive undertaking that requires commitment of time, capital, and manpower. For example, Burroughs Wellcome's antiviral discovery program was active for 6 years before acyclovir was synthesized in 1974 at the US facility. In the decade that followed, further R&D involving biologic activity screens (plaque reduction and inhibition) and preclinical work (mouse, guinea pig, and rabbit models) was done at the facility in England, ultimately requiring 330 "scientist years" and millions of pounds sterling. 24 Similarly, Imperial Chemical Industries' ␤-receptor antagonist program was active for 6 years before propranolol was synthesized in 1964. Sir James Black noted that his co-workers' use of deductive organic chemistry, understanding of the link between drug delivery and effect, and development of analytic methods for estimating the levels and tissue distribution of a drug and its metabolites were crucial to the discovery and development of propranolol. 25 Finally, Smith Kline & French's histamine H 2receptor antagonist program was initiated in 1964. By the mid-1970s, more than 700 compounds had been synthesized and tested for bioactivity; several (burimamide and metiamide) were tested in human subjects. Approximately 150 scientists were involved in the program. Cimetidine was synthesized in 1972, tested in normal volunteers in March 1975, first given to patients in November 1975, and marketed in England in November 1976. The rapid pace of the development program was a result of the knowledge gained from the work that had been done on the precursor compounds.
These examples illustrate the point that drug discovery is a time-consuming process requiring the synthesis and in vitro screening of many compounds before one with the best properties is selected for clinical testing. A priori, there is no guarantee that a drug discovery program will be successful. Moreover, even after a promising candidate is discovered, there are many more steps to the process (eg, formulation, sta-bility testing, preclinical testing) before the drug can be studied in the clinic ( Table 2) .
SUCCESS HAS MANY FATHERS
The composite history of the 21 impact drugs reveals that the public and private research spheres are symbiotic, sustaining each other in both expected and unexpected ways. The public sector is often responsible for basic science research that lays the groundwork for new drugs (eg, modern genetics laid the groundwork for interferon ␤-1b) or even research into new uses for old drugs. Still other public sector research contributes to the clinical knowledge used in the design of efficacy tests for discovered drugs (eg, finasteride) or epidemiologic and long-term health outcome studies (eg, the intervention studies of gemfibrozil by the US Department of Veterans Affairs) needed to establish new directions for drug-related studies, so-called agendasetting research. 26 Even those functions are interchangeable, however, because private sector development of new therapeutic agents often benefits basic research in the public sector by enabling scientists to explore the way the body works at the cellular level, such as occurred with cyclosporin and the immune system and with lovastatin and cholesterol biosynthesis. 27 Even drugs that are commercial failures for the drug companies can benefit the public sector, because the work done during discovery and development can yield important insight into human physiology and biochemistry. 28 The NIH has long recognized the integral role of the pharmaceutical industry. In its 1997 Director's Panel Report, the NIH stated as one of its 10 recommendations for the effective continuance of clinical research that the NIH should ". . . sustain a productive dialogue on enhancing clinical research with its partners: the academic health centers, private foundations, and the pharmaceutical and managed health care industries." 29 The NIH report notes that the $15.1 billion spent by research-based pharmaceutical companies in 1996 "makes the pharmaceutical industry the largest under in the aggregate of clinical research in the United States." 30 It also points out ". . . that the percentage of NIH's contribution to clinical research as a whole, although considerable . . . may be smaller relative to the other large contributors than was originally thought." 31 Both the public and private sectors bear the burdens and share the benefits of pharmaceutic R&D. Although the burdens and benefits may be different in nature, the risks are incurred in similar terms-time and money. Who should bear these risks? How should § Black was a research scientist at Imperial Chemical Industries, where he worked from 1958 to 1964 on the ␤-receptor antagonist program that resulted in the discovery and development of propranolol. He then moved to Smith Kline & French, where he worked from 1964 to 1972 on the H 2 -receptor antagonist program that resulted in the discovery and development of cimetidine. There are multiple sequential chemical or biologic reactions yielding desired intermediates; entire synthesis pathway must be charted and validated Time frame for completion of multiple sequential steps increases from 1 week to 1 month for each reaction step Preclinical, formulation, and stability tests: preclinical animal pharmacology and toxicology to determine potential risks of API to human beings and the environment Manufacturer must demonstrate company's capacity to produce a product in large volume and ensure chemical stability, batch-to-batch uniformity, and overall product quality Develop clinical trial design and protocol; select sites and assess qualifications, willingness, availability, and performance of investigators; prepare IND application; package, label, and deliver product to sites Involves use of animals, tissue culture, and other test systems to examine relation of dose, frequency of administration and duration of exposure to short-and long-term survival; requires veterinarians and toxicologists as well as animal and laboratory technicians Ramp-up production of API to kilogram levels; each of multiple steps in synthesis needs to be systematically investigated and scaled-up Early batches must be characterized for purity, impurity, and physical and chemical attributes to ensure that material to be tested in animals and human beings is identical to previous lots with consistent stability and bioavailability Develop comprehensive database of physical and chemical properties of API and biopharmacologic profile of molecule to evaluate impact of lot-to-lot variation on drug performance as a result of evolutionary changes in synthesis scale (i.e., the process of turning active compound into a form and strength suitable for human use Must be able to demonstrate sufficient stability that 90% of the API at a minimum and only 1% of degradation products at a maximum are present from time of manufacture until last subject, and last dose Requires preformulation, analytic, and formulation scientists
Costs of animal studies rose threeto sixfold from 1980-1990, testing in 2000 would range from $20,000 for acute rat toxicity study to $2 million for 2-year rat bioassay Drug has to show an adequate safety profile in animal toxicology testing Risk of new impurities as a result of larger scale operations, the addition of formulation excipients, and processing steps can alter bioavailability in human beings Risk that short-term stability may not predict long-term results Chemical and biologic studies must also be conducted whenever the dosage form, formulation, or manufacturing process is changed Formulation development alone can cost $1 million limited resources be apportioned among seemingly limitless needs? Funding of research, whether by the public or private sector, is an investment decision. The degree of uncertainty, the expected market value, and the potential social benefit are the key factors in determining the appropriate roles for the public and private sectors in health capital investment decisions. 32 Whether such funding is best supplied by the public or private sector involves the interplay of these three key factors. When there is a high level of uncertainty combined with potentially large social benefits in the absence of sufficient patent protection, there is a strong imperative for public investment. Conversely, when the expected market value is high and future use is predictable, private sector funding should suffice. A gray zone exists, however, whenever there is considerable uncertainty and unclear market value. Here, a collaboration of public and private funding is appropriate, with sharing of the risks and benefits. 33 Pharmaceutical companies are hard pressed to justify research when there is difficulty in obtaining exclusive economic benefits. Patent protection is essential for companies investing in pharmaceutic R&D. Unlike many other technologic advances, a drug product, once discovered, is relatively easy to reproduce. Without the period of market exclusivity that patents provide, companies would not have the opportunity to recoup their R&D investments. 34 Yet, patents do not grant complete monopoly power in the pharmaceutical industry, because competitors can discover and patent similar drugs that use the same basic mechanism to treat an illness. The first drug using the new mechanism to treat that illness-the pioneer drugusually has between 1 and 6 years on the market before a therapeutically similar patented drug ("me-too" drug) is introduced. 35 In fact, 7 of the 21 impact drugs examined here had a period of pioneer exclusivity of 6 years or less. 36 Both in the private sector and the public sector, "medical research, like medical practice, is increasingly, and reasonably, challenged to show value for money." 37 Pharmaceutical companies are no exception, and preserving the fruits of decades of labor through patents and regulatory grants of market exclusivity is one way firms can show value for money to risk-averse investors.
The public sector also has begun to appreciate the need to protect and profit from its intellectual capital. Over the last two decades, universities have made increasing use of the technology transfer laws passed in the early 1980s, especially the Bayh-Dole Act. Since its enactment, the number of patents issued to universities and the number of licenses granted by universities have increased 10-fold, and royalties paid to universities have nearly quadrupled. 38 For its part, the NIH recognizes the need to enhance its stewardship of the public's investment in drug discovery and development by enhancing data collection and public access to information on NIH funding of inventive research. Nevertheless, the NIH emphasizes that "requiring direct financial recoupment of the federal investment in biomedical research can potentially impede the development of promising technologies . . ." 39 Moreover, the NIH believes that recoupment strategies ". . . would destabilize a successful balance between public and private needs for innovation and development." 40 
SUMMARY
Our analysis indicates that the research reported in NIH's case study report and in Cockburn and Henderson's papers has been both misinterpreted and inappropriately used in quantitative analyses of the public and private contributions to drug discovery and development. Both the NIH's and Cockburn and Henderson's methodologies underestimate the contributions of the private sector. The outcome of the NIH's analysis of 47 top-selling drugs underscores this fact.
By the same token, our review of the history of 21 impact drugs further illustrates that it is illusory to assign ownership of drugs categorically. The biologic bases of the diseases alleviated by the 21 impact drugs as well as the chemical origins of the drugs themselves were the focus of decades of prior research efforts. The pieces of these research puzzles were pulled together over many decades by many researchers from many countries working in both the public and private sectors.
The "reality" of drug discovery is that it relies on a complex chain of interrelated events 41 and it involves an incremental learning process that takes place over time. 42 The basic research that underlies new therapeutic compounds is a combination of publicly available biomedical knowledge and basic research conducted by firms. 43 There is a high degree of complexity and creativity in the process of drug discovery. Nevertheless, there is a progression in research and learning. To the extent that firms monitor and use publicly available medical knowledge in their research, they can begin the process of drug innovation with something other than a "blank chalkboard." 44 Enormous changes have occurred within the drug R&D environment since the period during which the drugs discussed in this article first began the long road from test tube to pharmacy shelves. The biotechnology industry has flourished as a consequence of the passage of the Bayh-Dole Act and the availability of collaborations and alliances with major pharmaceutical firms. Today, the boundaries between publicly funded and privately sponsored medical research, which were never sharply defined, are even more unclear. 45 Now, as in the past, it is evident that the private sector needs the public sector "to do good science," 46 whereas the public sector needs the private sector to transform that scientific capital into products that benefit society and thus to do good medicine.
